BR112012021446A2 - polímero de amina, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, método para tratar doença, métodos de remoção de sais biliares de um indivíduo animal, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de amina. - Google Patents
polímero de amina, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, método para tratar doença, métodos de remoção de sais biliares de um indivíduo animal, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de amina.Info
- Publication number
- BR112012021446A2 BR112012021446A2 BR112012021446A BR112012021446A BR112012021446A2 BR 112012021446 A2 BR112012021446 A2 BR 112012021446A2 BR 112012021446 A BR112012021446 A BR 112012021446A BR 112012021446 A BR112012021446 A BR 112012021446A BR 112012021446 A2 BR112012021446 A2 BR 112012021446A2
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- amine polymer
- bile salts
- animal
- preparing
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 229920000642 polymer Polymers 0.000 title abstract 6
- 150000001412 amines Chemical class 0.000 title abstract 5
- 239000003833 bile salt Substances 0.000 title abstract 3
- 229940093761 bile salts Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000008214 LDL Cholesterol Methods 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002641 glycemic effect Effects 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 210000002966 serum Anatomy 0.000 title abstract 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract 1
- 206010069703 Bile acid malabsorption Diseases 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 abstract 1
- 239000003613 bile acid Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0206—Polyalkylene(poly)amines
- C08G73/0213—Preparatory process
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0206—Polyalkylene(poly)amines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/024—Polyamines containing oxygen in the form of ether bonds in the main chain
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0246—Polyamines containing other atoms than carbon, hydrogen, nitrogen or oxygen in the main chain
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0246—Polyamines containing other atoms than carbon, hydrogen, nitrogen or oxygen in the main chain
- C08G73/0253—Polyamines containing sulfur in the main chain
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0273—Polyamines containing heterocyclic moieties in the main chain
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/028—Polyamidoamines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
- C08L79/02—Polyamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30782210P | 2010-02-24 | 2010-02-24 | |
| US30782010P | 2010-02-24 | 2010-02-24 | |
| US37368210P | 2010-08-13 | 2010-08-13 | |
| PCT/US2011/026106 WO2011106548A1 (en) | 2010-02-24 | 2011-02-24 | Amine polymers for use as bile acid sequestrants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012021446A2 true BR112012021446A2 (pt) | 2016-05-31 |
Family
ID=43901141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012021446A BR112012021446A2 (pt) | 2010-02-24 | 2011-02-24 | polímero de amina, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, método para tratar doença, métodos de remoção de sais biliares de um indivíduo animal, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de amina. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9655920B2 (enExample) |
| EP (1) | EP2539389B1 (enExample) |
| JP (3) | JP6258586B2 (enExample) |
| KR (1) | KR101822608B1 (enExample) |
| CN (2) | CN107266681A (enExample) |
| AU (2) | AU2011220748B2 (enExample) |
| BR (1) | BR112012021446A2 (enExample) |
| CA (1) | CA2790901C (enExample) |
| DE (1) | DE112011100657T5 (enExample) |
| ES (1) | ES2661079T3 (enExample) |
| GB (1) | GB2490855A (enExample) |
| MX (1) | MX348821B (enExample) |
| RU (2) | RU2612795C2 (enExample) |
| WO (1) | WO2011106548A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9181364B2 (en) | 2010-02-24 | 2015-11-10 | Relypsa, Inc. | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants |
| US20150239824A1 (en) * | 2012-08-24 | 2015-08-27 | Universite De Strasbourg | Branched or macrocyclic polyamines and uses thereof |
| WO2014163883A2 (en) * | 2013-03-13 | 2014-10-09 | Elevance Renewable Sciences | Natural oil derivatives including primary amine functional groups |
| DK3287133T3 (da) * | 2013-06-05 | 2019-07-01 | Tricida Inc | Proton-bindende polymerer til oral indgivelse |
| MA41202A (fr) | 2014-12-18 | 2017-10-24 | Genzyme Corp | Copolymères polydiallymine réticulé pour le traitement du diabète de type 2 |
| MA41083A1 (fr) * | 2015-04-07 | 2018-05-31 | Intercept Pharmaceuticals Inc | Compositions pharmaceutiques pour thérapie combinée |
| WO2017024237A1 (en) * | 2015-08-06 | 2017-02-09 | The Johns Hopkins University | Composition and method for treatment of metabolic disorders |
| CN105111089B (zh) * | 2015-09-07 | 2017-05-10 | 南京华威医药科技开发有限公司 | 吡沙洛姆中间体 |
| CN106176800B (zh) * | 2016-07-11 | 2019-12-06 | 韩源平 | 多聚阳离子树脂的制药应用 |
| GB201809627D0 (en) * | 2018-06-12 | 2018-07-25 | Biorelevant Com Ltd | Methods for preparing buffer solutions suitable for in vitro drug dissolution testing, drug solubility testing and/or drug profiling |
| US11524029B2 (en) | 2018-08-13 | 2022-12-13 | Viscera Labs, Inc. | Therapeutic composition and methods |
| US11590161B2 (en) | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
| AU2020348451A1 (en) | 2019-09-20 | 2022-04-21 | Glyscend, Inc. | Substituted phenyl boronic acid containing polymers and methods of use |
| WO2024040380A1 (zh) * | 2022-08-22 | 2024-02-29 | 中美华世通生物医药科技(武汉)股份有限公司 | 铵盐聚合物及其制备方法和作为胆汁酸螯合剂的用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3692895A (en) * | 1970-09-08 | 1972-09-19 | Norman A Nelson | Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria |
| JPH066667A (ja) | 1992-06-22 | 1994-01-14 | Canon Inc | ぶれ検出装置及びぶれ補正装置 |
| EP0580079B1 (de) | 1992-07-22 | 1996-12-11 | Hoechst Aktiengesellschaft | Vernetzte, stickstoffhaltige Vinylcopolymere, Verfahren zu ihrer Herstellung sowie die Verwendung dieser Verbindungen |
| ES2110543T3 (es) | 1992-07-22 | 1998-02-16 | Hoechst Ag | Derivados de poli(vinil-aminas) que tienen centros hidrofilos, procedimiento para su preparacion asi como la utilizacion de los compuestos como medicamentos, vehiculos de sustancias activas e ingredientes auxiliares para alimentos. |
| SK31395A3 (en) * | 1992-08-20 | 1995-08-09 | Du Pont | Crosslinked polymeric ammonium salts |
| US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5414068A (en) | 1994-01-24 | 1995-05-09 | Rohm And Haas Company | Crosslinked anion exchange particles and method for producing the particles |
| TW474813B (en) * | 1994-06-10 | 2002-02-01 | Geltex Pharma Inc | Alkylated composition for removing bile salts from a patient |
| AU3585397A (en) | 1996-06-27 | 1998-01-14 | G.D. Searle & Co. | Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications |
| US6083497A (en) * | 1997-11-05 | 2000-07-04 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers |
| US7425579B2 (en) * | 1998-04-21 | 2008-09-16 | Universite Laval | Methods for inhibiting activity of polyamine transporters |
| US6294163B1 (en) | 1998-10-02 | 2001-09-25 | Geltex Pharmaceuticals, Inc. | Polymers containing guanidinium groups as bile acid sequestrants |
| WO2000038664A2 (en) | 1998-12-23 | 2000-07-06 | Geltex Pharmaceuticals, Inc. | Amine condensation polymer bile acid sequestrants |
| US7459502B2 (en) | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| US7608674B2 (en) * | 2003-11-03 | 2009-10-27 | Ilypsa, Inc. | Pharmaceutical compositions comprising cross-linked small molecule amine polymers |
| US7335795B2 (en) | 2004-03-22 | 2008-02-26 | Ilypsa, Inc. | Crosslinked amine polymers |
| JP2007517047A (ja) | 2003-12-31 | 2007-06-28 | ジェンザイム・コーポレーション | 腸溶コーティングされた脂肪族アミンポリマーの胆汁酸捕捉因子 |
| CN101065409A (zh) * | 2004-10-13 | 2007-10-31 | 伊立普萨公司 | 交联胺聚合物 |
| EP2511274A3 (en) * | 2005-01-21 | 2013-01-02 | Basf Se | Polyamine derivative |
| EP2016114A2 (en) | 2006-05-05 | 2009-01-21 | Genzyme Corporation | Amine condensation polymers as phosphate sequestrants |
| BRPI0715053A2 (pt) | 2006-07-18 | 2013-03-19 | Genzyme Corp | composiÇço farmacÊutica, mÉtodo para tratar doenÇas, e, polÍmero |
| BRPI0716066A2 (pt) | 2006-09-01 | 2013-09-17 | Genzyme Corp | composiÇço farmacÊutica, mÉtodo para tratar doenÇas, polÍmero de amina, rede polimÉrica, mÉtodo para preparar um polÍmero de amina, e, composto de amina |
| US8163799B2 (en) | 2006-12-14 | 2012-04-24 | Genzyme Corporation | Amido-amine polymer compositions |
| WO2008103368A1 (en) * | 2007-02-23 | 2008-08-28 | Genzyme Corporation | Amine polymer compositions |
| EP2152277A1 (en) | 2007-04-27 | 2010-02-17 | Genzyme Corporation | Amido-amine dendrimer compositions |
| WO2009023544A2 (en) * | 2007-08-10 | 2009-02-19 | Ilypsa, Inc. | Dosage unit anion-exchange polymer pharmaceutical compositions |
| JP5332520B2 (ja) * | 2007-11-07 | 2013-11-06 | アステラス製薬株式会社 | 医薬用錠剤 |
| WO2009097127A1 (en) | 2008-01-31 | 2009-08-06 | Genzyme Corporation | Pharmaceutical compositions |
| WO2009122400A1 (en) | 2008-03-31 | 2009-10-08 | Semorex Inc. | Phosphate binding polymers |
| US20110129433A1 (en) * | 2008-06-26 | 2011-06-02 | Ironwood Pharmaceuticals, Inc. | Compositions and Methods for Treating or Preventing Gastrointestinal Disorders and GERD-Related Respiratory Disorders |
| US9181364B2 (en) | 2010-02-24 | 2015-11-10 | Relypsa, Inc. | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants |
| CA2790899C (en) | 2010-02-24 | 2018-12-18 | Relypsa, Inc. | Polyimidazoles for use as bile acid sequestrants |
-
2011
- 2011-02-24 US US13/581,148 patent/US9655920B2/en not_active Expired - Fee Related
- 2011-02-24 ES ES11706453.5T patent/ES2661079T3/es active Active
- 2011-02-24 CA CA2790901A patent/CA2790901C/en not_active Expired - Fee Related
- 2011-02-24 CN CN201710479049.3A patent/CN107266681A/zh active Pending
- 2011-02-24 BR BR112012021446A patent/BR112012021446A2/pt not_active Application Discontinuation
- 2011-02-24 GB GB1216820.9A patent/GB2490855A/en not_active Withdrawn
- 2011-02-24 MX MX2012009783A patent/MX348821B/es active IP Right Grant
- 2011-02-24 JP JP2012555155A patent/JP6258586B2/ja not_active Expired - Fee Related
- 2011-02-24 EP EP11706453.5A patent/EP2539389B1/en not_active Not-in-force
- 2011-02-24 WO PCT/US2011/026106 patent/WO2011106548A1/en not_active Ceased
- 2011-02-24 RU RU2012140432A patent/RU2612795C2/ru active
- 2011-02-24 RU RU2017106587A patent/RU2017106587A/ru not_active Application Discontinuation
- 2011-02-24 CN CN201180019265.0A patent/CN102906159B/zh not_active Expired - Fee Related
- 2011-02-24 DE DE112011100657T patent/DE112011100657T5/de not_active Withdrawn
- 2011-02-24 AU AU2011220748A patent/AU2011220748B2/en not_active Ceased
- 2011-02-24 KR KR1020127024557A patent/KR101822608B1/ko not_active Expired - Fee Related
-
2016
- 2016-02-04 AU AU2016200700A patent/AU2016200700B2/en not_active Ceased
- 2016-03-24 JP JP2016059918A patent/JP2016130320A/ja active Pending
-
2017
- 2017-05-22 US US15/601,291 patent/US20170258825A1/en not_active Abandoned
- 2017-07-21 JP JP2017141886A patent/JP6622760B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120130227A (ko) | 2012-11-29 |
| RU2012140432A (ru) | 2014-03-27 |
| RU2017106587A (ru) | 2019-01-21 |
| GB201216820D0 (en) | 2012-11-07 |
| JP6622760B2 (ja) | 2019-12-18 |
| WO2011106548A1 (en) | 2011-09-01 |
| EP2539389A1 (en) | 2013-01-02 |
| EP2539389B1 (en) | 2017-12-20 |
| AU2016200700B2 (en) | 2017-08-17 |
| RU2612795C2 (ru) | 2017-03-13 |
| JP2017190464A (ja) | 2017-10-19 |
| US20140356316A1 (en) | 2014-12-04 |
| US9655920B2 (en) | 2017-05-23 |
| MX348821B (es) | 2017-06-30 |
| GB2490855A (en) | 2012-11-14 |
| ES2661079T3 (es) | 2018-03-27 |
| AU2016200700A1 (en) | 2016-02-25 |
| KR101822608B1 (ko) | 2018-01-29 |
| CN102906159B (zh) | 2017-09-26 |
| AU2011220748A1 (en) | 2012-09-20 |
| AU2011220748B2 (en) | 2015-11-05 |
| JP6258586B2 (ja) | 2018-01-10 |
| MX2012009783A (es) | 2012-11-21 |
| US20170258825A1 (en) | 2017-09-14 |
| CA2790901A1 (en) | 2011-09-01 |
| DE112011100657T5 (de) | 2013-02-28 |
| CA2790901C (en) | 2018-05-01 |
| JP2016130320A (ja) | 2016-07-21 |
| CN107266681A (zh) | 2017-10-20 |
| JP2013520563A (ja) | 2013-06-06 |
| CN102906159A (zh) | 2013-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012021444A2 (pt) | polímero de amina reticulado, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, métodos para tratar doença, de remoção de sais biliares de um indivíduo, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de aminas. | |
| BR112012021446A2 (pt) | polímero de amina, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, método para tratar doença, métodos de remoção de sais biliares de um indivíduo animal, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de amina. | |
| BR112012021448A2 (pt) | polímero de amina, método para tratar doença, método de remoção de sais biliares de um indivíduo animal, método para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de amina. | |
| BRPI0509366B8 (pt) | composição farmacêutica, kit farmacêutico, e, uso de uma composição farmacêutica | |
| BR112013032667A2 (pt) | polipeptídeo de ligação a pcsk9, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o polipeptídeo, composição farmacêutica, método de redução do nível de colesterol ldl em um sujeito, método de tratamento de disfunção relacionada ao colesterol em um sujeito, método de tratamento de hipercolesterolemia em um sujeito, método de inibição da ligação de pcsk9 a ldlr e método de detecção da proteína pcsk9 em uma amostra | |
| BR112012008282A2 (pt) | anticorpos de neutralização anti-nfg humanos como inibidores de curso de ngf seletivos | |
| BRPI0810246A2 (pt) | Inibidores da dpp-iv incluindo o grupo beta-amino, método de preparação do mesmo e composição farmacêutica contendo o mesmo para prevenção e tratamento da diabetes ou obesidade. | |
| EA201101524A1 (ru) | Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором | |
| CY1119010T1 (el) | Συνθεση και μεθοδος για τη θεραπευτικη αγωγη του διαβητη | |
| WO2013058833A8 (en) | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof | |
| BRPI0921687A2 (pt) | Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero. | |
| BRPI0821644A2 (pt) | Compostos derivados de benzimidazol carboxila ou hidroxila substituídos, processo para a sua preparação, composições farmacêuticas que os contêm, método para o tratamento terapêutico ou profilático de enfermidades que são moduladas por agonistas fxr e usos dos compostos | |
| BRPI0908107A2 (pt) | composto derivado de xantina substituída, composição farmacêutica que compreende esse composto, métodos de tratamento de uma enfermidade ou condição em um paciente com necessidade do mesmo, método de tratamento de enfermidade crônica dos rins, do fígado, relacionada com diabetes e de claudicação intermitente | |
| WO2012106363A3 (en) | Treatment of tauopathies | |
| BRPI0820578A2 (pt) | Vírus da varíola, processo para preparar um vírus da varíola, composição, uso de um vírus da varíola ou de uma composição, e, método para tratar doenças | |
| WO2008137236A3 (en) | Treatment of age-related macular degeneration using inhibitors of complement factor d | |
| BR112013015687A2 (pt) | anticorpo anti-pcsk9 ou um fragmento de anticorpo que se liga a pcsk9, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar um anticorpo anti-pcsk9, composição farmacêutica, método de redução do nível de colesterol ldl em um sujeito e método de tratamento de hipercolesterolemia em um sujeito | |
| EA200602210A1 (ru) | Связывающие молекулы, способные нейтрализовать вирус бешенства, и их применение | |
| BR112015003590A8 (pt) | Métodos para tratamento ou prevenção da asma por administração de um antagonista de il-4r | |
| BR112013000043A2 (pt) | derivados de ácido naft-2-ilacético para tratar aids | |
| JP2017503849A5 (enExample) | ||
| MX359570B (es) | Proteinas de union que inhiben la interaccion en el receptor de vegf-a. | |
| BR112013023561A2 (pt) | implante de ângulo composto | |
| EP2432761A4 (en) | TREATMENT OF MUSCLE DISEASE CHARACTERIZED BY INSULIN RESISTANCE | |
| BR112014011028A2 (pt) | molécula de ligação isolada ou fragmento de ligação de antígeno da mesma, anticorpo biespecífico, molécula de polinucleotídeo isolada, composição, método para a prevenção ou tratamento de uma infecção por pseudomonas em um indivíduo, e, kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |